Home » Topics » Regulatory » EMA

EMA
RSS

EMA gives positive scientific advice on approval pathway for Actinium's Iomab-B

March 22, 2017

EMA committee agrees on pediatric investigation plan for Macrilen

March 8, 2017

FDA and EMA accept for filing ertugliflozin submissions

March 7, 2017

European Commission approves Ledaga for mycosis fungoides-type CTCL

March 7, 2017

EMA grants orphan drug designation to Resolaris for limb girdle muscular dystrophy

March 6, 2017

EMA grants SPK-9001 access to PRIME program for hemophilia B

March 6, 2017

EMA grants PRIME access to givosiran for acute hepatic porphyrias

March 2, 2017

EMA committee hands down positive opinion for 8-week regimen of Viekirax + Exviera

March 1, 2017

EMA committee hands down positive opinion for Varuby

Feb. 27, 2017

EMA committee recommends broadening approval of Darzalex

Feb. 27, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...